SEMA6A-AS1: A Potential Drug Target and Biomarker (G101927233)

Target Name: SEMA6A-AS1

NCBI ID: G101927233

SEMA6A-AS1

Other Name(s): CTB-118N6.3 | SEMA6A antisense RNA 1

SEMA6A-AS1: A Potential Drug Target and Biomarker

SEMA6A-AS1, also known as CTB-118N6.3, is a protein that is expressed in various tissues and cell types in the human body. It is a member of the SEMA6A family, which is known for its role in cell signaling and adhesion. SEMA6A-AS1 has been identified as a potential drug target and biomarker due to its unique structure and expression pattern in various tissues.

The SEMA6A family consists of several proteins that are involved in cell signaling and adhesion. SEMA6A-AS1 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and muscle. It is highly conserved, with a calculated pI of 12.0, which makes it a potential drug target that can be targeted by small molecules.

SEMA6A-AS1 is involved in several cellular processes that are crucial for normal physiological function. One of its most significant functions is in cell adhesion and migration. SEMA6A-AS1 is a critical regulator of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and prevent excessive fluid leakage. It is also involved in the formation of adherens junctions, which are another type of cell-cell adhesion that helps to maintain tissue integrity.

In addition to its role in cell adhesion and migration, SEMA6A-AS1 is also involved in several signaling pathways that are important for normal cellular function. One of its most significant roles is in the regulation of theNotch signaling pathway. Notch signaling is a critical pathway that regulates cell proliferation, differentiation, and survival, and it is involved in the development and maintenance of tissues throughout the body. SEMA6A-AS1 is a critical regulator of Notch signaling in various tissues, and it has been shown to play a role in the regulation of stem cell proliferation and differentiation.

SEMA6A-AS1 is also involved in the regulation of several other signaling pathways, including NF-kappa, FGF, and Wnt. These signaling pathways are important for the development and maintenance of various tissues and organs, and SEMA6A-AS1 has been shown to play a critical role in their regulation.

As a potential drug target, SEMA6A-AS1 is an attractive target for small molecules due to its unique structure and expression pattern. SEMA6A-AS1 is a protein that is expressed in various tissues and cell types, which makes it an attractive target for small molecules that can be administered to a wide range of cells. Additionally, its high conservation and stability make it a stable target for small molecules, which is important for the development of safe and effective drugs.

In addition to its potential as a drug target, SEMA6A-AS1 is also a potential biomarker. Its unique expression pattern and structure make it an attractive candidate for use as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. SEMA6A-AS1 has been shown to be expressed in a variety of tissues and cell types, including cancer cells, which makes it an potential biomarker for cancer. Additionally, its involvement in several signaling pathways makes it an potential biomarker for neurodegenerative diseases.

In conclusion, SEMA6A-AS1 is a protein that is expressed in various tissues and cell types in the human body. Its unique structure and high conservation make it a potential drug target and biomarker. Its involvement in several cellular processes, including cell adhesion and migration, and its regulation of several signaling pathways make it an attractive target for small molecules. Further research is needed to fully understand the role of SEMA6A-AS1 in cellular processes and its potential as a drug

Protein Name: SEMA6A Antisense RNA 1

The "SEMA6A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEMA6A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets